Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer

Cancer Letters

Volumn 98, Issue 2, 1996, Pages 151-155

  Kohlberger, P ^a   Loesch, A ^a   Koelbl, H ^a   Breitenecker, G ^a   Kainz, Ch ^a   Gitsch, G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Endometrial cancer; HER 2 neu oncoprotein; Immunohistochemistry; Prognosis

Indexed keywords

GLYCOPROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0030045523     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(06)80025-X     Document Type: Article

References (26)

1. Mack, T.M., Cozen, W. and Quinn, M.A. (1992) Epidemiology of cancer of the endometrium, ovary, vulva and vagina. In: Gynecologic Oncology, pp. 31-54. Editor: M. Coppleson. Churchill Livingstone, Edinburgh.
2. Gitsch, G., Friedlander, M.L., Wain, G.V. and Hacker, N.F. (1995) Uterine papillary serous carcinoma. A clinical study. Cancer, 75, 2239-2243.
3. Gitsch, G., Hanzal, E., Jensen, D. and Hacker, N.F. (1995) Endometrial cancer in premenopausal women 45 years and younger. Obstet. Gynecol., 85, 504-508.
4. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T. and Toyoshima, K. (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature, 319, 230-234.
5. Wright, C., Angus, B., Nicholson, S., Sainsbury, R.C., Cairns, J., Gullick, W.J., Kelly, P., Harris, A.L. and Wilson Home, C.H. (1989) Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res., 49, 2087-2090.
6. Walker, R.A., Senior, P.V., Jones, J.L., Critchley, D.R. and Varley, J.M. (1989) An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. J. Pathol., 158, 97-105.
7. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 77-182.
8. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J.T., Dodge, R., Clarke-Pearson, D.L., Marks, P., McKenzie, S., Yin, S. and Bast, R.C. (1990) Overexpression of HER-2-neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50, 4087-4091.
9. Sato, K., Moriyama, M., Mori, S., Saito, M., Watanuki, T., Terada, K., Okuhara, E., Akiyama, T., Toyoshima, K., Yamamoto, T. and Kato, T. (1992) An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 70, 2493-2498.
10. Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M. and Sasaki, T. (1991) Evaluation of Immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res, 49, 1034-1038.
11. Yonemura, Y., Nakai, Y., Takamura, H., Hirono, Y., Fujimura, T., Sugiyama, K., Fonseca, L., Tsugawa, K., Ninomiya, I., Miyazaki, I., Sasaki, T., Endou, Y. and Tanaka, M. (1993) Prediction of the prognosis of patients with gastric cancer by erbB-2 tissue status and expression of proliferating cell nuclear antigen. Int. J. Oncol., 2, 1033-1037.
12. Malviya, V.K., Deppe, G., Malone, Jr., J.M., Sundareson, A.S. and Lawrence, W.D. (1989) Reliability of frozen section examination in identifying poor prognostic indicators in stage I endometrial adenocarcinoma. Gynecol. Oncol., 34, 299-304.
13. Morrow, C.P., Bundy, B.N., Kurmann, R.J., Creasman, W.T., Heller, P., Homesley, H.D. and Graham, J.E. (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol., 40, 55-65.
14. Hermanek, P. and Sobin, L.H. (Editors) (1992) UICC TNM Classification of Malignant Tumours. 4th edn., 2nd rev. Springer-Verlag, Berlin.
15. FIGO stages (1989) 1988 Revision, Announcements. Gynecol. Oncol., 35, 125-127.
16. Kaplan, E.L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc., 53, 457-481.
17. Hacker, N.F. (1994) Uterine Cancer. In: Practical Gynecologic Oncology, pp. 285-314. Editors: J.S. Berek and N.F. Hacker. Williams and Wilkins, Baltimore, MD.
18. Coussens, L., Yang-Feng, T.L., Liao, Y.C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Libermann, T.A., Schlessinger, J., Francke, U. et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139.
19. Berchuck, A., Rodriguez, G., Kinney, R.B., Soper, J.T., Dodge, R.K., Clarke-Pearson, D.L. and Bast, Jr., R.C. (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol., 164, 15-21.
20. Wang, D.-p., Konishi, I., Koshiyama, M., Mandai, M., Nanbu, Y., Ishikawa, Y., Mori T. and Fujii, S. (1993) Expression of c-erB-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer, 72, 2628-2637.
21. Hetzel, D.J., Wilson, T.O., Keeney, G.L., Roche, P., Cha, S.S. and Podratz, K.C. (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol., 47, 179-185.
22. Bigsby, R.M., Aixin, L., Bomalaski, J., Stehman, F.B., Look, K.Y. and Sutton, G.P. (1992) Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet. Gynecol., 79, 95-100.
23. Pisani, A.L., Barbuto, D.A., Dwight, Chen, Ramos, L., Lagasse, L.D. and Karlan, B.Y. (1995) HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet. Gynecol., 85, 729-734.
24. Reinartz, J.J., George, E., Lindgren, B.R. and Niehans, G.A. (1994) Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum. Pathol., 25, 1075-1083.
25. Lukes, A.S., Kohler, M.F., Pieper, C.F., Kerns, B.J., Bentley, R., Rodriguez, G.C., Soper, J.T., Clarke-Pearson, D.L., Bast, Jr., R.C. and Berchuck, A. (1994) Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer, 73, 2380-2385.
26. Nielsen, A.L. and Nyholm, H.C.J. (1994) p53 and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections. Am. J. Clin. Pathol., 102, 76-79.